Physician profile
Amber Scrivner
NPI 1821098856
$1,399.50
in general payments reported to CMS, 2019-2025
15 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $294 · 2023: $333 · 2024: $388 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.84 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $251.43 | 2022-2024 | |
| Organon LLC | $158.98 | 2021-2023 | Nexplanon |
| Astellas Pharma US INC | $135.16 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $80.61 | 2021-2024 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $56.62 | 2022 | |
| Avion Pharmaceuticals | $53.26 | 2022-2023 | Balcoltra |
| Hologic Sales and Service, LLC | $47.63 | 2024-2025 | Aptima |
| Pfizer INC. | $44.81 | 2021-2024 | |
| Exeltis, USA INC. | $41.75 | 2022-2025 | Slynd |
| Millicent US INC | $39.10 | 2023-2024 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $24.91 | 2022 | |
| Sumitomo Pharma America, INC. | $19.94 | 2023 | Myfembree |
| Mylan Pharmaceuticals INC. | $19.14 | 2022 | |
| Myriad Women'S Health, INC. | $14.32 | 2023 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Scrivner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.